Pharma & Life Sciences Enterprise (201-1000 employees)

Drug Safety Associate at Enterprise

High Conscientiousness and Emotional Stability to process ICSRs, meet expedited reporting deadlines, and maintain the pharmacovigilance database.

In enterprise pharma, multi-market regulatory complexity is the norm

10-15 year development cycles require genuine long-term vision

Pharmacovigilance and patient safety are non-delegable responsibilities

Ideal OCEAN+ Profile

Openness 58 Conscientiousness 98 Extraversion 46 Agreeableness 75 Emotional Stability 74 Structure & Rhythm 83
Ideal range
Openness
50 65

At enterprise companies (201-1000 employees), ability to interpret complex cases, identify emerging signals, and adapt processes to new ICH E2 guidelines and local regulations

Conscientiousness
95 100

At enterprise companies (201-1000 employees), precision in documenting adverse events, meeting expedited deadlines (7/15 days), and maintaining the pharmacovigilance database

Extraversion
37 55

At enterprise companies (201-1000 employees), communication with physicians and reporters to obtain additional case information; internal presentations of safety metrics

Agreeableness
68 82

At enterprise companies (201-1000 employees), collaboration with medical, regulatory, and legal teams to evaluate and manage complex safety cases

Emotional Stability
67 81

At enterprise companies (201-1000 employees), tolerance for peak case volumes, pressure from regulatory deadlines, and the distressing nature of serious adverse event report content

Structure & Rhythm
75 90

At enterprise companies (201-1000 employees), the pharmacovigilance associate operates under regulatory reporting deadlines for adverse events (15 days for SUSARs, 7 days for fatal cases) and defined case-handling processes; adherence to case processing pace is non-negotiable

Strengths and Red Flags

Strengths

  • Accurate, on-time processing of ICSRs within expedited regulatory deadlines
  • Maintaining the quality and consistency of the safety database
  • Managing product portfolios across multiple development and commercialization phases
  • Robust regulatory compliance with FDA, EMA, and local health authorities

Red Flags

  • Case processing errors that cause expedited reports to miss deadlines
  • Inconsistent MedDRA term coding that compromises signal detection
  • Paralysis in the face of complex multi-product, multi-phase portfolios
  • Internal bureaucracy that delays go/no-go pipeline decisions

Interview Questions

How many cases do you process on average per month? What is your expedited deadline compliance rate, and how do you handle volume spikes?

Evaluates: Conscientiousness and management of high-precision operational workload

Describe your process for coding MedDRA terms on a case with multiple adverse events. What criteria do you use to select the most appropriate term?

Evaluates: Conscientiousness and technical rigor in safety processing

How did you manage a multi-product portfolio across different development phases?

Evaluates: Systemic vision and prioritization capacity at scale

How did you coordinate a multi-market regulatory registration process?

Evaluates: Conscientiousness and coordination in highly complex environments

More about Drug Safety Associate

Career path, personality archetypes and similar roles in the full profile.

This Role in Other Contexts

Does your next Drug Safety Associate at Enterprise (201-1000 employees) match this profile?

Map anyone's OCEAN+ profile with the Talent Diagnostic: free, no signup, 10 minutes.

20 statements · 10 minutes · no card